Evidence map›Paper›PMID 35748105›Full record

ArticleAnnals of clinical and translational neurology2022

Psychotropic medication use and Parkinson's disease risk amongst older women.

Hind A Beydoun, Nazmus Saquib, Robert B Wallace, Jiu-Chiuan Chen, Mace Coday, Michelle J Naughton, May A Beydoun, Aladdin H Shadyab, Alan B Zonderman, Robert L Brunner

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Psychotropic medication use and Parkinson's disease risk amongst older women.Annals of clinical and translational neurology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Hind A BeydounDepartment of Research Programs, Fort Belvoir Community Hospital, Fort Belvoir, Virginia, 22060, USA.ORCID 0000-0002-9704-328X
Nazmus SaquibDepartment of Research, College of Medicine, Sulaiman AlRajhi University, Al Bukayriah, Kingdom of Saudi Arabia.
Robert B WallaceDepartment of Epidemiology and Internal Medicine, University of Iowa, Iowa City, Iowa, 52242, USA.
Jiu-Chiuan ChenDepartments of Population & Public Health Sciences and Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, 90089.
Mace CodayDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA.
Michelle J NaughtonDepartment of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, 43201, USA.
May A BeydounLaboratory of Epidemiology and Population Sciences, National Institute on Aging, NIA/NIH/IRP, Baltimore, Maryland, 21225, USA.ORCID 0000-0002-1050-4523
Aladdin H ShadyabHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, 92093, USA.
Alan B ZondermanLaboratory of Epidemiology and Population Sciences, National Institute on Aging, NIA/NIH/IRP, Baltimore, Maryland, 21225, USA.
Robert L BrunnerDepartment of Family and Community Medicine (Emeritus), School of Medicine, University of Nevada (Reno), Auburn, California, 95602, USA.
National Institute on Aging · USAlexander T. Augusta Military Medical Center · USSulaiman Al Rajhi Colleges · SAThe Ohio State University · USUniversity of California San Diego · USUniversity of Iowa · USUniversity of Nevada, Reno · USUniversity of Southern California · USUniversity of Tennessee Health Science Center · US

Funding

WOMEN'S HEALTH INITIATIVE - CLINICAL COORDINATING CENTER: TASK AREA B - LONG LIFE STUDY VISIT 2 LIMITED HOME VISIT75N92021D00001 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L. · 2021 to 2025
$52.0M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI HANS-JOACHIM LEHMLER · 1990 to 2026
$40.5M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00002 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WACTAWSKI-WENDE, JEAN · 2021 to 2025
$6.9M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00004 · NHLBI · STANFORD UNIVERSITY · PI STEFANICK, MARCIA · 2021 to 2025
$6.5M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00003 · NHLBI · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA · 2021 to 2025
$5.0M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI VITOLINS, MARA · 2021 to 2025
$4.2M
NHLBI NIH HHS 75N92021D00001NHLBI NIH HHS 75N92021D00002NIEHS NIH HHS P30 ES005605WHI NIH HHS 75N92021D00003WHI NIH HHS 75N92021D00004WHI NIH HHS 75N92021D00005
6 · The paper itself

Abstract

objectiveTo examine associations of antidepressant, anxiolytic and hypnotic use amongst older women (≥65 years) with incident Parkinson's Disease (PD), using data from Women's Health Initiative linked to Medicare claims.

methodsPD was defined using self-report, first diagnosis, medications and/or death certificates and psychotropic medications were ascertained at baseline and 3-year follow-up. Cox regression models were constructed to calculate adjusted hazard ratios (aHR) with 95% confidence intervals (CI), controlling for socio-demographic, lifestyle and health characteristics, overall and amongst women diagnosed with depression, anxiety and/or sleep disorders (DASD).

resultsA total of 53,996 WHI participants (1,756 PD cases)-including 27,631 women diagnosed with DASD (1,137 PD cases)-were followed up for ~14 years. Use of hypnotics was not significantly associated with PD risk (aHR = 0.98, 95% CI: 0.82, 1.16), whereas PD risk was increased amongst users of antidepressants (aHR = 1.75, 95% CI: 1.56, 1.96) and anxiolytics (aHR = 1.48, 95% CI: 1.25, 1.73). Compared to non-users of psychotropic medications, those who used 1 type had ~50% higher PD risk, whereas those who used ≥2 types had ~150% higher PD risk. Women who experienced transitions in psychotropic medication use ('use to non-use' or 'non-use to use') between baseline and 3-year follow-up had higher PD risk than those who did not. We obtained similar results with propensity scoring and amongst DASD-diagnosed women.

interpretationThe use of antidepressants, anxiolytics or multiple psychotropic medication types and transitions in psychotropic medication use was associated with increased PD risk, whereas the use of hypnotics was not associated with PD risk amongst older women.

Indexed as

Anti-Anxiety AgentsParkinson DiseaseAgedAntidepressive AgentsFemaleHumansHypnotics and SedativesMedicarePsychotropic DrugsUnited StatesAnti-Anxiety AgentsAntidepressive AgentsHypnotics and SedativesPsychotropic Drugs

Identifiers

PMID35748105
PMCPMC9380147
OpenAlexW4283362967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.